Mentor, Ohio-based STERIS plc (STE) provides infection prevention products and services in the United States and internationally. The company has a market cap of $22.6 billion and operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences, and offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, instruments, and more.
STE is expected to release its Q2 2027 earnings on Wednesday, November 4, 2026, after the market closes. Ahead of the event, analysts expect the company’s EPS to be $2.67 on a diluted basis, up 8.1% from $2.47 in the year-ago quarter. The company has met or exceeded Wall Street’s EPS estimates in three of its last four quarters, while missing on one occasion.
For fiscal 2027, analysts project the company’s EPS to be $11.12, up 9.3% from $10.17 in fiscal 2026. Moreover, its EPS is expected to rise by roughly 10.3% year over year (YoY) to $12.26 in fiscal 2028.
STE stock has declined 4.2% over the past 52 weeks, underperforming the S&P 500 Index’s ($SPX) 14.4% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 24.2% rise during the same time frame.
On Aug. 5, STE stock declined marginally following the release of its mixed Q1 2027 earnings. The company’s revenue for the quarter rose 7.3% from the prior year’s quarter to $1.5 billion and came in line with the Street’s forecasts. Moreover, its adjusted EPS came in at $2.59, surpassing Wall Street’s estimates. However, its free cash flow margin amounted to 18.7%, down from 23.5% in the year-ago quarter, indicating profitability troubles and operational inefficiency.
Analysts are somewhat optimistic about STE, with the stock having a “Moderate Buy” rating overall. Among the nine analysts covering the stock, six are recommending a “Strong Buy,” and three suggest a “Hold.” STE’s average analyst price target is $261.75, indicating an upside of 12.7% from the current level.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.